Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05445440 | A Study to Assess the Effects of BMS-986371 on the Drug Levels of Methotrexate in the Presence and Absence of Sulfasalazine | PHASE1 | COMPLETED | 30 | — | — | Sep 6, 2022 | Nov 23, 2022 | Feb 8, 2023 | 1 | United States |
Part 1
Part 1
Part 1
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | - |
| Part 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Methotrexate | DRUG | Specified dose on specified days |
| Leucovorin | DRUG | Specified dose on specified days |
| BMS-986371 | DRUG | Specified dose on specified days |
| Sulfasalazine | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participant has physical exam, vital signs, clinical laboratory safety and other medical test results that are within normal limits, considered not clinically significant by the Investigator, or within other parameters specified in the protocol * Body mass index of 18 to 32 kg...